NYSE:JNJPharmaceuticals
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
Johnson & Johnson (NYSE:JNJ) reported multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology, and myeloma.
The company highlighted first in class efficacy signals for FcRn-blocker nipocalimab in systemic lupus erythematosus (SLE) and promising outcomes in Sjögren's disease.
Phase 3 data for prostate cancer and myeloma therapies were described as practice changing in scope, with potential to influence future treatment standards and regulatory plans.
For...